Evidence map›Paper›PMID 35496516›Full record

ArticleRSC advances2020

Amphiphilic irinotecan-melampomagnolide B conjugate nanoparticles for cancer chemotherapy.

Wenhao Qu, Quanjun Yang, Guanchun Wang, Zhaohong Wang, Ping Huang, Wei Huang, Rong Zhang, Deyue Yan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Wenhao QuSchool of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University 800 Dongchuan Road Shanghai 200240 China hw66@sjtu.edu.cn hp158@sjtu.edu.cn.
Quanjun YangDepartment of Pharmacy, Shanghai Jiao Tong University Affiliated Sixth People's Hospital 600 Yishan Road Shanghai 200233 China.
Guanchun WangSchool of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University 800 Dongchuan Road Shanghai 200240 China hw66@sjtu.edu.cn hp158@sjtu.edu.cn.
Zhaohong WangSchool of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University 800 Dongchuan Road Shanghai 200240 China hw66@sjtu.edu.cn hp158@sjtu.edu.cn.
Ping HuangSchool of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University 800 Dongchuan Road Shanghai 200240 China hw66@sjtu.edu.cn hp158@sjtu.edu.cn.
Wei HuangSchool of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University 800 Dongchuan Road Shanghai 200240 China hw66@sjtu.edu.cn hp158@sjtu.edu.cn.ORCID https://orcid.org/0000-0002-7885-4378
Rong ZhangDepartment of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499 China rongzhang@163.com.
Deyue YanSchool of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University 800 Dongchuan Road Shanghai 200240 China hw66@sjtu.edu.cn hp158@sjtu.edu.cn.ORCID https://orcid.org/0000-0002-8681-0332
Shanghai Jiao Tong University · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melampomagnolide B (MMB) is a natural sesquiterpene lactone product structurally related to parthenolide (PTL). Although MMB has been widely used to treat various types of cancers, such as glioma, leukemia and colon cancer, the effective delivery of MMB to cancer cells remains a challenge. An amphiphilic drug-drug conjugate (ADDC) strategy has been proposed and developed as a promising drug self-delivery system for cancer therapy because of its simple preparation, carrier-free nature, and high therapeutic activity. Herein, we present a new ADDC, which is synthesized by linking the hydrophilic anticancer drug irinotecan (Ir) and the hydrophobic anticancer drug MMB through a carbonate bond. The obtained amphiphilic irinotecan-melampomagnolide B conjugate (Ir-C-MMB) can self-assemble in water into stable nanoparticles with an average diameter of around 122.1 nm. After cellular uptake, the carbonate bond between the hydrophilic drug and hydrophobic drug can be cleaved to release free Ir and MMB under acidic conditions, which exhibit a synergistic effect in tumor cells. MTT results reveal that the Ir-C-MMB nanoparticles can effectively inhibit proliferation of cancer cells. The apoptosis data indicate that the apoptosis rate of cells treated with Ir-C-MMB nanoparticles is about 50% within 24 h, which is much higher than that of free Ir or MMB. Our results suggest that this ADDC strategy could be used as a drug delivery platform for MMB and its derivatives, and that it offers effective synergistic therapeutic efficacy.

Identifiers

PMID35496516
PMCPMC9050120
OpenAlexW3009421817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.